← Back to Search

Alkylating agents

MEDI5752 + Chemotherapy for Pleural Mesothelioma (eVOLVE-Meso Trial)

Phase 3
Recruiting
Led By Marjorie G Zauderer, MD
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically proven diagnosis of pleural mesothelioma with known histology (epithelioid vs. non-epithelioid)
Participant must be ≥ 18 years at the time of screening
Must not have
Active or prior documented autoimmune or inflammatory disorders
Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human immunodeficiency virus (HIV) infection that is not well controlled
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12, 18, 24, 36 months
Awards & highlights
Pivotal Trial
No Placebo-Only Group

Summary

This trial is testing a new drug called Volrustomig combined with two chemotherapy drugs, Carboplatin and Pemetrexed. It targets adult patients with advanced pleural mesothelioma that cannot be removed by surgery. The treatment aims to help the immune system fight the cancer while also killing cancer cells directly.

Who is the study for?
This trial is for adults over 18 with advanced, inoperable pleural mesothelioma. They must have stable health without significant deterioration in the past two weeks and measurable disease per specific criteria. Excluded are those with certain infections (TB, HBV, HCV, HIV), autoimmune or inflammatory disorders, another primary cancer (with exceptions), uncontrolled illnesses, or untreated brain metastases.
What is being tested?
The study compares the effectiveness of Volrustomig combined with Carboplatin and Pemetrexed against either platinum plus Pemetrexed or Nivolumab plus Ipilimumab. It's a phase III trial where participants are randomly assigned to receive one of these treatments to see which works best for unresectable pleural mesothelioma.
What are the potential side effects?
Potential side effects include reactions related to immune system activation such as inflammation in various organs, infusion-related reactions from the drugs being administered intravenously, fatigue from treatment burden on the body's resources, possible blood cell count changes affecting immunity and oxygen transport.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer is confirmed as pleural mesothelioma and its type is known.
Select...
I am 18 years old or older.
Select...
My condition cannot be cured with surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have or had an autoimmune or inflammatory disorder.
Select...
I do not have uncontrolled TB, HBV, HCV, or HIV.
Select...
I do not have any unmanaged ongoing illnesses.
Select...
I am not currently receiving any cancer treatments like chemotherapy or radiotherapy.
Select...
My cancer has spread to my brain and hasn't been treated or is getting worse.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12, 18, 24, 36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12, 18, 24, 36 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Survival (OS) in experimental arm relative to comparator arm
Secondary study objectives
Area under the curve (AUC)
Disease-related symptoms using EORTC IL305 (Q1)
Disease-related symptoms using PRO-CTCAE (Q1, 5, 6, 9)
+14 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Volrustomig + Carboplatin + pemetrexedExperimental Treatment3 Interventions
Volrustomig in combination with carboplatin plus pemetrexed
Group II: Investigator's choice of standard careActive Control5 Interventions
The investigator's choice of nivolumab plus ipilimumab or platinum plus pemetrexed chemotherapy for participants with epithelioid histology, and nivolumab plus ipilumab for participants with non-epithelioid histology.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~6120
Pemetrexed
2014
Completed Phase 3
~5550

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Pleural Mesothelioma include chemotherapy, immunotherapy, and investigational therapies such as bispecific antibodies. Chemotherapy, often using drugs like pemetrexed and cisplatin, works by targeting rapidly dividing cancer cells, thereby slowing disease progression. Immunotherapy, including agents like nivolumab and ipilimumab, enhances the body's immune response against cancer cells by inhibiting immune checkpoints that cancer cells exploit to evade detection. Bispecific antibodies, such as Volrustomig (MEDI5752), target multiple immune checkpoints simultaneously, potentially offering a more robust anti-tumor response. These treatments are crucial for Pleural Mesothelioma patients as they can improve survival rates and quality of life by effectively managing the disease and alleviating symptoms.
Novel and Future Treatment Options in Mesothelioma: A Systematic Review.

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,427 Previous Clinical Trials
289,163,999 Total Patients Enrolled
Marjorie G Zauderer, MDPrincipal InvestigatorMemorial Slone Kettering (MSK) Cancer Centre
Arnaud Scherpereel, MDPrincipal InvestigatorLille University
~390 spots leftby Mar 2027